JP2022541646A5 - - Google Patents
Info
- Publication number
- JP2022541646A5 JP2022541646A5 JP2022505209A JP2022505209A JP2022541646A5 JP 2022541646 A5 JP2022541646 A5 JP 2022541646A5 JP 2022505209 A JP2022505209 A JP 2022505209A JP 2022505209 A JP2022505209 A JP 2022505209A JP 2022541646 A5 JP2022541646 A5 JP 2022541646A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- cdr3
- antibody
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902642 | 2019-07-25 | ||
| AU2019902642A AU2019902642A0 (en) | 2019-07-25 | Methods and agents for treating acute neuroinflammatory injury | |
| PCT/US2020/043619 WO2021016601A1 (en) | 2019-07-25 | 2020-07-24 | Methods and agents for treating acute neuroinflammatory injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541646A JP2022541646A (ja) | 2022-09-26 |
| JP2022541646A5 true JP2022541646A5 (enExample) | 2023-07-31 |
Family
ID=74192699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505209A Pending JP2022541646A (ja) | 2019-07-25 | 2020-07-24 | 急性神経炎症傷害を処置するための方法および薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220249610A1 (enExample) |
| EP (1) | EP4003518A4 (enExample) |
| JP (1) | JP2022541646A (enExample) |
| KR (1) | KR20220040478A (enExample) |
| CN (1) | CN114450068A (enExample) |
| AU (1) | AU2020316519A1 (enExample) |
| IL (1) | IL290046A (enExample) |
| WO (1) | WO2021016601A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144141A1 (en) * | 2018-01-22 | 2019-07-25 | UNIVERSITY OF VIRGINIA PATENT FOUNDATION d/b/a UNIVERSITY OF VIRGINIA LICENSING & VENTURE | System and method for automated detection of neurological deficits |
| CN116367858A (zh) * | 2020-09-10 | 2023-06-30 | 隐式生物科技有限公司 | 用于治疗心肌梗塞的治疗方法和试剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820858A (en) | 1993-05-28 | 1998-10-13 | The Scripps Research Institute | Methods and compositions for inhibiting CD14 mediated cell activation |
| AU2001290315A1 (en) | 2000-11-22 | 2002-06-03 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| WO2006063292A1 (en) | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| CA2609262A1 (en) * | 2005-06-03 | 2006-12-07 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 antibody fusion protein |
| PL2034830T3 (pl) * | 2006-05-25 | 2015-04-30 | Biogen Ma Inc | Przeciwciało anty-VLA-1 do leczenia udaru |
| WO2008088902A2 (en) * | 2007-01-17 | 2008-07-24 | Yale University | Attenuation of the adaptive immune response |
| WO2018165720A1 (en) * | 2017-03-17 | 2018-09-20 | Implicit Bioscience Pty Ltd | Agents for treating or preventing viral infections and uses therefor |
| IL309046B2 (en) * | 2017-04-21 | 2025-03-01 | Implicit Bioscience Ltd | CD14 antagonist antibodies for the treatment of neurodegenerative diseases |
-
2020
- 2020-07-24 CN CN202080067788.1A patent/CN114450068A/zh active Pending
- 2020-07-24 JP JP2022505209A patent/JP2022541646A/ja active Pending
- 2020-07-24 WO PCT/US2020/043619 patent/WO2021016601A1/en not_active Ceased
- 2020-07-24 US US17/629,763 patent/US20220249610A1/en active Pending
- 2020-07-24 EP EP20843606.3A patent/EP4003518A4/en active Pending
- 2020-07-24 KR KR1020227006319A patent/KR20220040478A/ko active Pending
- 2020-07-24 AU AU2020316519A patent/AU2020316519A1/en active Pending
-
2022
- 2022-01-23 IL IL290046A patent/IL290046A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531254A5 (enExample) | ||
| CN101827609B (zh) | 抗人神经生长因子的高亲和力人抗体 | |
| KR102597804B1 (ko) | 이중 특이적 항체 | |
| JP2022036944A (ja) | Ｒｇｍ ａタンパク質に対するモノクローナル抗体及びその使用 | |
| AU2020277207A1 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| KR102308493B1 (ko) | 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2019511911A5 (enExample) | ||
| JP2021527640A5 (enExample) | ||
| JP2006020633A (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| JP2019527194A5 (enExample) | ||
| HK1201847A1 (en) | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases | |
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| JP2023549067A5 (enExample) | ||
| JP2018529635A5 (enExample) | ||
| US10618974B2 (en) | Anti-TrkA antibody | |
| JP2018509390A5 (enExample) | ||
| JP2013508292A5 (enExample) | ||
| JP2024054119A (ja) | 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法 | |
| JP2017507131A5 (enExample) | ||
| JP2016094424A5 (enExample) | ||
| JP2023536904A5 (enExample) | ||
| JP2022541646A5 (enExample) | ||
| TW202003582A (zh) | 頭頸癌之治療 | |
| KR20210089719A (ko) | Hla-감작된 환자에서 탈감작화 및 신장 이식의 개선을 위한 클라자키주맙의 용도 | |
| JP2023537078A5 (enExample) |